Empagliflozin reduces left ventricular volumes in patients with HFrEF

  • Lee MMY & al.
  • Circulation
  • 13 Nov 2020

  • curated by Sarfaroj Khan
  • UK Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Treatment with sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin led to significant reductions in left ventricular (LV) volumes (LV end-systolic volume index [LVESVi] and LV end-diastolic volume index [LVEDVi]), as well as reductions in N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with heart failure with reduced ejection fraction (HFrEF) and type 2 diabetes (T2D) or prediabetes.
  • However, no improvement was seen in LV global longitudinal strain (LV GLS).

Why this matters

  • Findings suggest that favourable reverse LV remodeling may be a mechanism by which SGLT2 inhibitor empagliflozin reduces HF hospitalisation and mortality in HFrEF.

Study design

  • In this SUGAR-DM-HF trial, 105 patients with HFrEF and T2D or prediabetes were randomly assigned (1:1) to receive empagliflozin or placebo.
  • Co-primary outcomes: change in LVESVi and LV GLS from baseline to 36 weeks measured using cardiovascular magnetic resonance (CMR).
  • Funding: Boehringer Ingelheim.

Key results

  • 82 patients (78.1%) had diabetes and 23 (21.9%) had prediabetes; mean LV ejection fraction was 32.5%.
  • Empagliflozin vs placebo group had a significant reduction in:
    • LVESVi (adjusted between-group difference, −6.0 mL/m2; 95% CI, −10.8 to −1.2; P=.015);
    • LVEDVi (adjusted between-group difference, −8.2 mL/m2; 95% CI, −13.7 to −2.6; P=.004); and
    • NT-proBNP (adjusted between-group difference, −28%; 95% CI, −47 to −2%; P=.038).
  • No difference in LV GLS was seen between the empagliflozin and placebo groups (adjusted between-group difference, 0.35; 95% CI, −0.25 to 0.95; P=.25).
  • No between-group differences were seen in:
    • other CMR measures;
    • Kansas City Cardiomyopathy Questionnaire Total Symptom Score;
    • 6-minute walk distance; and
    • B-lines on lung ultrasound and biomarkers (including NT-proBNP).

Limitations

  • Patients with atrial fibrillation or cardiac devices were not included to avoid image degradation.